The Exclusive Right Buyout of Sanofi’s Ophthalmology Antibodies by Regeneron
Sanofi and Regeneron are old partners that have worked together for many times and gained achievements, for example the colon-cancer drug Zaltrap and REGN727.
On May 3, 2013, Regeneron Pharmaceuticals announced two preclinical programs for its growing business in ophthalmologydrugs and it has forked over $20 million upfront and promised up to $45 million in milestones to its major partner, Sanofi, for full rights to the pair of antibody programs for use against eye diseases.
The deal amends the collaboration between Sanofi and Regeneron for the antibodies that target receptors for platelet-derived growth factor (PDGF) and the angiopoietin2 (ANG2) receptor and ligand for eye ailments.
In the terms of agreement, Regeneron agreed to pay Sanofi $10 million in upfront cash, $40 million in potential milestones and royalties for full rights to PDGF antibodies. For full rights to the ANG2 candidates in eye disease, Regeneron will pay out $10 million initially as well as $5 million in milestones and royalties to Sanofi.
Sanofi has kept rights to the ANG2 program for uses outside of eye diseases, including the REGN910 candidate in Phase I development for advanced tumors.